Difference between revisions of "RhoA"
(New page: {{Subst:infobox}}) |
|||
| Line 1: | Line 1: | ||
| − | |||
{| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | {| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | ||
! {{infobox header}}| '''{{PAGENAME}}''' | ! {{infobox header}}| '''{{PAGENAME}}''' | ||
| Line 12: | Line 11: | ||
|- | |- | ||
| Determination type | | Determination type | ||
| − | | In situ | + | | In situ/In vitro |
|- | |- | ||
| Source | | Source | ||
| Line 21: | Line 20: | ||
|- | |- | ||
| Swissprot ID | | Swissprot ID | ||
| − | | [http://au.expasy.org/uniprot/ | + | | [http://au.expasy.org/uniprot/P06749 P06749 ] |
|- | |- | ||
| Reactive glutamines | | Reactive glutamines | ||
| − | | [[ | + | | [[Q52, Q63, Q136 (RhoA)|Q52, Q63, Q136]] |
|- | |- | ||
| Reactive lysines | | Reactive lysines | ||
| − | | | + | | - |
|- | |- | ||
| Substrate sequence | | Substrate sequence | ||
| − | | | + | | EVDGK''Q''VELAL |
| + | |||
| + | WDTAG''Q''EDYDR | ||
| + | |||
| + | LAKMK''Q''EPVKP | ||
|- | |- | ||
| Structure | | Structure | ||
| − | | [http://www.rcsb.org/pdb/explore/explore.do?structureId= | + | | [http://www.rcsb.org/pdb/explore/explore.do?structureId=1A2B 1A2B] |
|- | |- | ||
| Surface accessibility | | Surface accessibility | ||
| Line 42: | Line 45: | ||
|- | |- | ||
| Reference | | Reference | ||
| − | | [http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids= | + | | [http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=9593707&dopt=Abstract PMID:9593707] |
|- | |- | ||
| Notes | | Notes | ||
| − | | | + | | Q63 is deamidated/transamidated by TG2 |
| + | |||
| + | The transamidated protein has increased binding affinity to ROCK-2. The deamidated form (by cytotoxic dermonecrotizing factor or BTX) has decreased GTPase activity. | ||
|- | |- | ||
| {{infobox header}} | | | {{infobox header}} | | ||
Revision as of 05:16, 24 July 2007
| Template:Infobox header| RhoA | |
|---|---|
| RhoA | |
| Substrate peptide name | RhoA |
| Synonyms | - |
| Determination type | In situ/In vitro |
| Source | Homo sapiens |
| Subcellular localization | Cytoskeleton |
| Swissprot ID | P06749 |
| Reactive glutamines | Q52, Q63, Q136 |
| Reactive lysines | - |
| Substrate sequence | EVDGKQVELAL
WDTAGQEDYDR LAKMKQEPVKP |
| Structure | 1A2B |
| Surface accessibility | ASAView pdf |
| Disorder prediction | IUPred |
| Reference | PMID:9593707 |
| Notes | Q63 is deamidated/transamidated by TG2
The transamidated protein has increased binding affinity to ROCK-2. The deamidated form (by cytotoxic dermonecrotizing factor or BTX) has decreased GTPase activity. |
| Template:Infobox header | | |
